anti-VWF antibody product blog
Tags: Antibody; Von Willebrand Factor; VWF; Monoclonal Antibody; anti-VWF antibody;
The VWF vwf (Catalog #MBS219690) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s VON WILLEBRAND FACTOR can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Immunohistology Paraffin*, Protein Purification (PP), Radioimmunoassays (RIA).Immunohistology - Paraffin: Minimum Dilution: 1/50; Maximum Dilution: 1/200; Application Note: This product requires protein digestion pre-treatment of paraffin sections e.g. trypsin or pronase. Researchers should empirically determine the suitability of the VWF vwf for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The VWF vwf product has the following accession number(s) (GI #89191868) (NCBI Accession #NP_000543.2) (Uniprot Accession #P04275). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given antibody. We\'ve tested the MOUSE ANTI HUMAN VON WILLEBRAND FACTOR with the following immunoassay(s):
Testing Data (Staining of paraffin embedded human liver sections with Mouse anti human Von Willebrand Factor (MBS219591))
Mouse anti Human von Willebrand factor antibody, clone RFF-VIII R/1 recognizes human von Willebrand factor (vWF), also known as Factor VIII related antigen, a blood glycoprotein involved in blood coagulation. It stabilises circulating Factor VIII by binding to it and protecting it from cleavage and delivers it to sites of vascular injury. vWF also promotes the adhesion of platelets to sites of vascular damage by forming a molecular bridge between collagen on exposed endothelial cells and the GPIb binding sites of platelets circulating in the blood. vWF circulates in the blood as large multimers, with each monomer (250kDa) containing a number of specific domains. Hereditary or acquired defects in vWF lead to von Willebrand disease (vWD), characterised by varying degrees of susceptibility to bleeding. Symptoms might include nosebleeds, bleeding gums, easy bruising, menorrrhagia or gastrointestinal bleeding. Various forms of vWD exist with differing severities, determined by the type of defect. Mouse anti Human von Willebrand factor, clone RFF-VIII R/1 has a high affinity for an epitope within the platelet GPIb-binding site that is responsible for biological activity. As such the antibody is a potent inhibitor of vWF activity. It can completely neutralise ristocetin-induced platelet aggregation and ristocetin-induced binding of vWF to platelets. It also inhibits platelet adhesion to glass beads. The epitope recognized is present only on the intact multimeric form of vWF and is abolished by mild denaturation with SDS. Mouse anti Human von Willebrand factor, clone RFF-VIII R/1 does not recognize human Factor VIII. Clone RF-VIII R/1 may be used as a capture antibody in immunoassays for vWF in combination with clone RFF-VIII R/2 as a detection reagent.